Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZoetisXSWX:ZTS +0.79%56 Intrinsic Value: Projected FCF is CHF47.69 as of Aug. 31, 2026. GuruFocus rates XSWX:ZTS with a GF Score™ of 56/100 and a GF Value™ of CHF147.84 (Significantly Undervalued). Among 632 Drug Manufacturers companies, Zoetis ranks better than 61.23% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-31), Zoetis's Intrinsic Value: Projected FCF is CHF47.69. The stock price of Zoetis is CHF61.26. Therefore, Zoetis's Price-to-Intrinsic-Value-Projected-FCF of today is 1.3.
The historical rank and industry rank for Zoetis's Intrinsic Value: Projected FCF or its related term are showing as below:
XSWX:ZTS'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.19 Med: 3.89 Max: 5.38
Current: 1.28
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Zoetis was 5.38. The lowest was 1.19. And the median was 3.89.
XSWX:ZTS's Price-to-Projected-FCF is ranked better than 61.23% of 632
companies
in the Drug Manufacturers industry
Industry Median: 1.575
vs XSWX:ZTS: 1.28
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Zoetis's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
61.26
/
45.785341875407
=
1.34
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis Intrinsic Value: Projected FCF Related Terms
Zoetis Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Zoetis's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ZTS vs UTHR, VTRS, NBIX: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zoetis's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Zoetis's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of CHF47.69 mean?
Zoetis (XSWX:ZTS) has a Intrinsic Value: Projected FCF of CHF47.69 as of Aug. 31, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Zoetis and its competitors. According to the industry distribution chart, Zoetis ranks #245 out of 632 companies in the Drug Manufacturers industry, placing it in the top 38.8%.
Is Zoetis' Intrinsic Value: Projected FCF too high?
Zoetis' current Intrinsic Value: Projected FCF is CHF47.69. Based on the distribution chart, Zoetis ranks #245 out of 632 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zoetis has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' Intrinsic Value: Projected FCF compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #245 out of 632 companies for Intrinsic Value: Projected FCF. This puts Zoetis in the upper half of its industry. The industry median Intrinsic Value: Projected FCF is 1.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.58, based on 632 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Zoetis and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zoetis's current Intrinsic Value: Projected FCF is CHF47.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (XSWX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF147.84, compared to a current price of CHF61.26 — trading 58.6% below its estimated fair value. The current Intrinsic Value: Projected FCF is CHF47.69. Zoetis' overall GF Score™ is 56/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Zoetis (XSWX:ZTS), the current Intrinsic Value: Projected FCF is CHF47.69 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zoetis (XSWX:ZTS) Overvalued in 2026?
Based on GuruFocus' analysis, Zoetis stock appears to be undervalued.
The current stock price of CHF61.26 is trading 58.6% below its estimated GF Value™ of CHF147.84.
GuruFocus considers Zoetis to be Significantly Undervalued.
Key valuation signals for XSWX:ZTS:
Intrinsic Value: Projected FCF: CHF47.69
GF Value™: CHF147.84 vs. price of CHF61.26 (58.6% below fair value)
No single metric tells the full story. See the XSWX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
56GF Score
Get the complete analysis for XSWX:ZTS
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZTS has been successfully added to your 
